The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review

• Autores: Nikhil Seval, Alysse Wurcel, Craig G. Gunderson, Sandra A. Springer
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 34, Nº. 3, 2020 (Ejemplar dedicado a: Infectious Disease Complications of Opioid Use and Other Substance Use Disorders), págs. 559-584
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hepatitis C virus (HCV) is highly prevalent in those with opioid use disorders (OUD) and injustice-involved populations.

    The data on the effect of medication treatments for OUD (MOUD eg, methadone, buprenorphine, extended-release naltrexone) on HCV incidence in prisons and jails are limited.

    MOUD effect on HCV incidence in prisons and jails was mixed in part due to the variability in each individual risk environment, suggesting the need for additional harm reduction such as syringe service programs